What is the dosing for diltiazem (calcium channel blocker) in the treatment of acute supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diltiazem Dosing for Acute SVT Treatment

For acute SVT in hemodynamically stable patients, administer diltiazem 0.25 mg/kg (approximately 15-20 mg for average adults) IV over 2 minutes, followed by a second dose of 0.35 mg/kg (20-25 mg) after 15 minutes if the first dose fails to convert the rhythm. 1, 2, 3

Initial Bolus Dosing

  • First dose: 0.25 mg/kg IV administered over 2 minutes 1, 2, 3
  • Second dose (if needed): 0.35 mg/kg IV given 15 minutes after the first dose if no therapeutic response occurs 2, 3, 4
  • Expected response time: Conversion typically occurs within 2-3 minutes of administration, with maximal heart rate reduction in 2-7 minutes 3, 4
  • Success rate: Diltiazem terminates SVT in 82-100% of patients, depending on the dose used 4, 5, 6

Maintenance Infusion (If Needed)

  • Start continuous infusion at 5 mg/hour after successful bolus conversion 2
  • Titrate up to 15 mg/hour based on heart rate response 2
  • Duration of effect after bolus: Heart rate reduction may last 1-3 hours; after 24-hour infusion, effects may persist 0.5 to >10 hours (median 7 hours) 3

Critical Contraindications - Do Not Use Diltiazem If:

  • Pre-excited atrial fibrillation/flutter (WPW syndrome or visible accessory pathway): May cause ventricular fibrillation and hemodynamic collapse 7, 2, 3
  • Second or third-degree AV block without pacemaker 2, 3
  • Decompensated heart failure or severe LV systolic dysfunction: Negative inotropic effects can worsen hemodynamics 7, 2
  • Hypotension or cardiogenic shock 2, 3
  • Sick sinus syndrome without pacemaker 2
  • Hemodynamically unstable patients: Proceed directly to synchronized cardioversion instead 7, 2

Place in Treatment Algorithm

  • First-line: Vagal maneuvers should be attempted first 7, 3
  • Second-line: Adenosine is the preferred initial pharmacologic agent due to rapid action and short half-life 1, 2
  • Third-line: Diltiazem is an excellent option when adenosine fails or is contraindicated 7, 1, 2
  • Diltiazem is more effective than esmolol for SVT termination 7, 5

Monitoring Requirements During Administration

  • Continuous ECG monitoring is mandatory throughout administration 2, 3
  • Frequent blood pressure measurements during bolus and infusion 2, 3
  • Defibrillator and resuscitation equipment must be immediately available 1, 2, 3

Common Adverse Effects and Management

  • Hypotension: Most common adverse effect (occurs in 3-7% of patients), usually short-lived but may persist 1-3 hours 3, 4, 8
    • Manage with IV fluids or Trendelenburg position; 3.2% of patients require intervention 3
  • Bradycardia: May require atropine or temporary pacing if severe 1
  • Worsening heart failure in predisposed patients 1

Critical Pitfall to Avoid

Never combine diltiazem with beta-blockers acutely - this combination can cause profound bradycardia and heart block 2

Mechanism of Action

Diltiazem works by slowing AV node conduction, increasing AV node refractoriness, and prolonging the AV nodal effective refractory period 1, 9, 6

Long-Term Oral Management After Conversion

  • Start at 120 mg daily (divided or single dose with long-acting formulations) 1
  • Maximum daily dose: 360 mg 1
  • Oral diltiazem is recommended for ongoing management in patients who are not candidates for or prefer not to undergo catheter ablation 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.